Comment
In the article below , the Center for Research on globalization insinuates that the US government is claiming to have invented the Ebola Virus from Uganda. The truth is that the US government created that virus and that is why it has secured a patent for it.The center also wonders what US biological war researchers are doing in the zone. The answer is simple; they are there to test the effectiveness of the new Ebola virus biological weapon in order to prepare for a new patent. There is the argument that , the patent is for a method of detecting and isolating a sample of the virus. In other words this is not a patent on the virus itself. This argument is nonsensical. Can the US allow a country such as Cuba or Russia to also develop a different patent on detecting and Isolating the Ebola sample.?
Must read:
Ebola as a US neo-imperialistic weapon: Portray Africans as poor helpless zombies: Come in as a solution to the Ebola virus you have created : Use this pretext to steal their mineral resources : Obama: Ebola crisis 'spiraling out of control' : US military to help Ebola effort
Why Do the U.S. Centers for Disease Control (CDC) Own a Patent on Ebola “Invention?”
Patent applicants are clearly described on the patent as including:
The Government Of The United States Of America As Represented By The Secretary, Department Of Health & Human Services, Center For Disease Control.
The patent summary says, “The invention provides the isolated human Ebola (hEbola) viruses denoted as Bundibugyo (EboBun) deposited with the Centers for Disease Control and Prevention (“CDC”; Atlanta, Georgia, United States of America) on November 26, 2007 and accorded an accession number 200706291.”
It goes on to state, “The present invention is based upon the isolation and identification of a new human Ebola virus species, EboBun. EboBun was isolated from the patients suffering from hemorrhagic fever in a recent outbreak in Uganda.”
It’s worth noting, by the way, that EboBun is not the same variant currently believed to be circulating in West Africa. Clearly, the CDC needs to expand its patent portfolio to include more strains, and that may very well be why American Ebola victims have been brought to the United States in the first place. Read more below and decide for yourself…
Harvesting Ebola from victims to file patents
From the patent description on the EboBun virus, we know that the U.S. government:
1) Extracts Ebola viruses from patients.
2) Claims to have “invented” that virus.
3) Files for monopoly patent protection on the virus.
It brings up the obvious question here: Why would the U.S. government claim to have “invented” Ebola and then claim an exclusively monopoly over its ownership?
U.S. Government claims exclusive ownership over its “invention” of Ebola
The “SUMMARY OF THE INVENTION” section of the patent document also clearly claims that the U.S. government is claiming “ownership” over all Ebola viruses that share as little as 70% similarity with the Ebola it “invented”:
…invention relates to the isolated EboBun virus that morphologically and phylogenetically relates to known members filoviridae… In another aspect, the invention provides an isolated hEbola EboBun virus comprising a nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of: a) a nucleotide sequence set forth in SEQ ID NO: 1; b) a nucleotide sequence that hybridizes to the sequence set forth in SEQ ID NO: 1 under stringent conditions; and c) a nucleotide sequence that has at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity to the SEQ ID NO:1. In another aspect, the invention provides the complete genomic sequence of the hEbola virus EboBun.
Ebola vaccines and propagation
The CDC patent goes on to explain it specifically claims patent protection on a method for propagating the Ebola virus in host cells as well as treating infected hosts with vaccines:
In another aspect, the invention provides a method for propagating the hEbola virus in host cells comprising infecting the host cells with the inventive isolated hEbola virus described above, culturing the host cells to allow the virus to multiply, and harvesting the resulting virions.No medical reason to bring Ebola to the United States
In another aspect, the invention provides vaccine preparations, comprising the inventive hEbola virus, including recombinant and chimeric forms of the virus, nucleic acid molecules comprised by the virus, or protein subunits of the virus. The invention also provides a vaccine formulation comprising a therapeutically or prophylactically effective amount of the inventive hEbola virus described above, and a pharmaceutically acceptable carrier.
This patent may help explain why Ebola victims are being transported to the United States and put under the medical authority of the CDC. These patients are carrying valuable intellectual property assets in the form of Ebola variants, and the Centers for Disease Control clearly desires to expand its patent portfolio by harvesting, studying and potentially patenting new strains or variants.
Dr. Bob Arnot, an infectious disease specialist who spent time on the ground in developing nations saving lives, recently told Judge Jeanine, “There is no medical reason to bring them here, especially when you see how well Dr. Bradley was.” (2)
There is, however, an entirely different reason to bring Ebola patients to America: so they can be exploited for medical experiments, military bioweapons harvesting or intellectual property claims.
Surely, medical authorities at Emory University and the CDC are working hard to save the lives of the two patients who have been transported to the U.S. But they are also pursuing something else at the same time: an agenda of isolating, identifying and patenting infectious disease agents for reasons that we can only imagine.
Only hoping to save lives?
On one hand, it’s worth pointing out that the CDC’s patent on Ebola is at least partially focused on methods for screening for Ebola and treating Ebola victims with drugs or vaccines. This seems like a worthwhile precaution against an infectious disease that clearly threatens lives.
On the other hand, why the patent? Patenting Ebola seems as odd as trying to patent cancer or diabetes. Why would a government organization claim to have “invented” this infectious disease and then claim a monopoly over its exploitation for commercial use?
Does the CDC hope to collect a royalty on Ebola vaccines? Is it looking to “invent” more variants and patent those too?
Make no mistake that billions of dollars in profits are at stake in all this. Shares of Tekmira surged over 11% last Friday as pressure was placed on the FDA to fast-track Ebola vaccine trials the company has set up. “Health campaigners have started a petition which has already been signed by approximately 15,500 people on change.org pressurizing FDA to approve the drug in the minimum possible time frame,” reports BidnessEtc.com. (3)
Carefully scripted medical theater
With this, we start to see the structure of the elaborate medical theater coming together: A global pandemic panic, a government patent, the importation of Ebola into a major U.S. city, an experimental vaccine, the rise of a little-known pharmaceutical company and a public outcry for the FDA to fast-track the vaccine.
If Act II stays on course, this medical theater might someday involve a “laboratory accident” in a U.S. lab, the “escape” of Ebola into the population, and a mandatory nationwide Ebola vaccination campaign that enriches Tekmira and its investors while positioning the CDC with its virus patents as the “savior of the American people.”
Yes, we’ve heard this music before, but the last time around it was called Swine Flu.
The formula is always the same: create alarm, bring a vaccine to market, then scare governments into buying billions of dollars worth of vaccines they don’t need.
West Africa: What are US Biological Warfare Researchers Doing in the Ebola Zone?
What exactly have they been doing?
Exactly what diagnostic tests have they been performing on citizens of Sierra Leone?
Why do we have reports that the government of Sierra Leone has recently told Tulane researchers to stop this testing?
Have Tulane researchers and their associates attempted any experimental treatments (e.g., injecting monoclonal antibodies) using citizens of the region? If so, what adverse events have occurred?
The research program, occurring in Sierra Leone, the Republic of Guinea, and Liberia—said to be the epicenter of the 2014 Ebola outbreak—has the announced purpose, among others, of detecting the future use of fever-viruses as bioweapons.
Is this purely defensive research? Or as we have seen in the past, is this research being covertly used to develop offensive bioweapons?
For the last several years, researchers from Tulane University have been active in the African areas where Ebola is said to have broken out in 2014.
These researchers are working with other institutions, one of which is USAMRIID, the US Army Medical Research Institute of Infectious Diseases, a well-known center for biowar research, located at Fort Detrick, Maryland.
In Sierra Leone, the Tulane group has been researching new diagnostic tests for hemorrhagic fevers.
Note: Lassa Fever, Ebola, and other labels are applied to a spectrum of illness that result in hemorrhaging.
Tulane researchers have also been investigating the use of monoclonal antibodies as a treatment for these fevers—but not on-site in Africa, according to Tulane press releases.
Here are excerpts from supporting documents.
Tulane University, Oct. 12, 2012, “Dean’s Update: Update on Lassa Fever Research” (.pdf here):
“In 2009, researchers received a five-year $7,073,538 grant from the National Institute of Health to fund the continued development of detection kits for Lassa viral hemorrhagic fever.
“Since that time, much has been done to study the disease. Dr. Robert Garry, Professor of Microbiology and Immunology, and Dr. James Robinson, Professor of Pediatrics, have been involved in the research of Lassa fever. Together the two have recently been able to create what are called human monoclonal antibodies. After isolating the B-cells from patients that have survived the disease, they have utilized molecular cloning methods to isolate the antibodies and reproduce them in the laboratory. These antibodies have been tested on guinea pigs at The University of Texas Medical Branch in Galveston and shown to help prevent them from dying of Lassa fever…
“Most recently, a new Lassa fever ward is being constructed in Sierra Leone at the Kenema Government Hospital. When finished, it will be better equipped to assist patients affected by the disease and will hopefully help to end the spread of it.” [The Kenema Hospital is one of the centers of the Ebola outbreak.]
“The initial round of clinical testing has been completed for the first diagnostic test kits that will aid in bioterrorism defense against a deadly viral disease. Tulane University researchers are collaborating in the project.
“Robert Garry, professor of microbiology and immunology at Tulane University, is principal investigator in a federally funded study to develop new tests for viral hemorrhagic fevers.
“Corgenix Medical Corp., a worldwide developer and marketer of diagnostic test kits, announced that the first test kits for detection of hemorrhagic fever have competed initial clinical testing in West Africa.
“The kits, developed under a $3.8 million grant awarded by the National Institutes of Health, involve work by Corgenix in collaboration with Tulane University, the U.S. Army Medical Research Institute of Infectious Diseases, BioFactura Inc. and Autoimmune Technologies.
“Clinical reports from the studies in Sierra Leone continue to show amazing results,” says Robert Garry, professor of microbiology and immunology at the Tulane University School of Medicine and principal investigator of the grant.
“We believe this remarkable collaboration will result in detection products that will truly have a meaningful impact on the healthcare in West Africa, but will also fill a badly needed gap in the bioterrorism defense.
“…The clinical studies are being conducted at the Mano River Union Lassa Fever Network in Sierra Leone. Tulane, under contract with the World Health Organization, implements the program in the Mano River Union countries (Sierra Leone, Liberia and Guinea) to develop national and regional prevention and control strategies for Lassa fever and other important regional diseases.
“Clinical testing on the new recombinant technology demonstrates that our collaboration is working,” says Douglass Simpson, president of Corgenix. “We have combined the skills of different parties, resulting in development of some remarkable test kits in a surprisingly short period of time. As a group we intend to expand this program to address other important infectious agents with both clinical health issues and threat of bioterrorism such as ebola.”
Why? Are the tests issuing false results? Are they frightening the population? Have Tulane researchers done something to endanger public health?
In addition to an investigation of these matters, another probe needs to be launched into all vaccine campaigns in the Ebola Zone. For example. HPV vaccine programs have been ongoing. Vials of vaccine must be tested to discover ALL ingredients. Additionally, it’s well known that giving vaccines to people whose immune systems are already severely compromised is dangerous and deadly.
Thanks to birdflu666.wordpress.com for discovering hidden elements of the Ebola story.
Jon Rappoport
The author of three explosive collections, THE MATRIX REVEALED, EXIT FROM THE MATRIX, and POWER OUTSIDE THE MATRIX, Jon was a candidate for a US Congressional seat in the 29th District of California. He maintains a consulting practice for private clients, the purpose of which is the expansion of personal creative power. Nominated for a Pulitzer Prize, he has worked as an investigative reporter for 30 years, writing articles on politics, medicine, and health for CBS Healthwatch, LA Weekly, Spin Magazine, Stern, and other newspapers and magazines in the US and Europe. Jon has delivered lectures and seminars on global politics, health, logic, and creative power to audiences around the world. You can sign up for his free emails at www.nomorefakenews.com